正电子发射断层显像/计算机体层摄影与磁共振成像在晚期宫颈癌接受根治性同步放化疗后疗效评估中的比较
研究纳入55例接受根治性同步放化疗的晚期宫颈癌(鳞癌)患者,于治疗完成后2至3个月行[18F]氟脱氧葡萄糖PET/CT与含扩散加权成像的盆腔/腹部MRI,采用同一评分系统独立判读。以病理证实或放化疗后一年内影像学疾病进展为活动性残留肿瘤标准,PET/CT在患者层面分析及局部、区域病灶检出方面均显著优于MRI,但两者灵敏度均欠佳。
要点
- 55例中15例(27%)存在活动性残留肿瘤,PET/CT患者层面灵敏度60%、特异度100%、准确率89%,MRI分别为27%、100%、80%。
- PET/CT在患者层面(P=0.025)、局部病灶(P=0.045)及区域病灶(P=0.014)检出方面均显著优于MRI。
- 因影像灵敏度欠佳,阴性或不确定结果的患者应定期随访。
核心结论
- 在晚期宫颈癌根治性同步放化疗后2至3个月,PET/CT对治疗后评估优于MRI,主要用于检出残留局部和区域病灶。
- 因影像灵敏度欠佳,阴性或不确定结果的患者应定期随访。
研究设计与样本
- 纳入宫颈鳞状细胞癌、FIGO分期为晚期或盆腔/腹主动脉旁淋巴结(PALN)阳性的患者,在同步放化疗完成后2至3个月行[18F]氟脱氧葡萄糖PET/CT及含扩散加权成像的MRI。
- PET/CT由两名核医学医师独立判读,MRI由两名放射科医师判读,采用同一评分系统。
- 活动性残留肿瘤以病理证实或同步放化疗后一年内影像学疾病进展为证,病灶区域分为局部、区域、PALN或远处。
- 采用受试者工作特征曲线分析进行患者层面和区域层面比较,共纳入55例患者。
主要发现
- 55例患者中15例(27%)存在活动性残留肿瘤。
- 患者层面分析中PET/CT诊断性能显著优于MRI(P=0.025)。
- 局部病灶检出中PET/CT显著优于MRI(P=0.045),区域病灶检出中PET/CT显著优于MRI(P=0.014)。
- 患者层面PET/CT灵敏度60%、特异度100%、准确率89%,MRI灵敏度27%、特异度100%、准确率80%。
关键数值与推荐
- 活动性残留肿瘤判定标准为病理证实或同步放化疗后一年内影像学疾病进展。
- 患者层面PET/CT灵敏度60%、特异度100%、准确率89%;MRI灵敏度27%、特异度100%、准确率80%。
- 患者层面比较P=0.025,局部病灶比较P=0.045,区域病灶比较P=0.014。
临床怎么用
- 作者结论认为PET/CT在晚期宫颈癌根治性同步放化疗后2至3个月的治疗后评估中优于MRI,主要用于检出残留局部和区域病灶。
- 作者指出因影像灵敏度欠佳,阴性或不确定结果的患者应定期随访。
局限性
- 原文指出影像灵敏度欠佳,阴性或不确定结果的患者应定期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to assess the diagnostic performance of positron emission tomography/computed tomography (PET/CT) and pelvic/abdominal magnetic resonance imaging (MRI) after concurrent chemoradiotherapy (CCRT) for posttherapy evaluation in patients with advanced cervical cancer. METHODS: Patients with cervical squamous cell carcinoma, either with advanced FIGO stage or with positive pelvic or para-aortic lymph node (PALN), received PET/CT using [18F]fluorodeoxyglucose and MRI including diffusion-weighted imaging between 2 and 3 months after CCRT completion. PET/CT were interpreted independently by two nuclear medicine physicians and MRI by two radiologists using the same scoring system. Active residual tumor was proven by pathological confirmation or disease progression on imaging studies within one year after CCRT and the disease regions were classified as local, regional, PALN, or distant. Patient-based and region-based comparison was performed using the receiver operating characteristic curve analysis. RESULTS: The study included 55 patients and 15 (27%) patients had active residual tumor. The diagnostic performance of PET/CT is significantly superior to that of MRI in patient-based analysis (P = 0.025) and in the detection of local (P = 0.045) and regional (P = 0.014) disease. The patient-based sensitivity, specificity, and accuracy of PET/CT are 60%, 100%, and 89% while those of MRI are 27%, 100%, and 80%. CONCLUSIONS: PET/CT is superior to MRI for posttherapy evaluation in patients with advanced cervical cancer 2-3 months after definitive CCRT, mainly for the detection of residual local and regional disease. Patients with negative or equivocal results should be followed up regularly due to suboptimal sensitivities of imaging.
引用
- Su TP, Lin G, Huang YT, et al. Comparison of positron emission tomography/computed tomography and magnetic resonance imaging for posttherapy evaluation in patients with advanced cervical cancer receiving definitive concurrent chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2017. PMID: 29159572. doi:10.1007/s00259-017-3884-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。